Thought Leadership

  • Omnichannel

    KOLs For An Omnichannel World

    The world your future KOLs inhabit now is far removed from the world your current KOLs have thrived in. The behaviours of tomorrow’s leaders and audiences are almost indistinguishable from those we’ve been used to for so long.

    Read more
  • Rising Stars / Emerging Experts

    Rising Stars: Whose Rank is it Anyway?

    Traditionally people tend to identify and rank rising stars by defined metrics – their number of publications, their academic qualifications and awards, their involvement in trials or guidelines.

    Read more
  • KOL Identification

    Finding KOLs For Innovative Therapies Is Not Straightforward

    You have in front of you a syndicated KOL database of gargantuan proportions showing you everyone with any sort of activity in your therapy area. You have a million names with metrics to match.

    Read more
  • KOL Influence Drives KOL Engagement

    From KOL List To KOL Action: The Role Of KOL Influence

    You have a truly innovative medicine with a unique proposition in an area with a clear unmet need – in other words, a perfect recipe for advancing patient well-being and achieving brand leadership.

    Read more
  • KOL Identification and KOL Mapping

    The Failure Of Quant-Led KOL Identification in Growth Markets

    When it comes to KOL identification mapping, there is no shortage of quant data around KOL and HCP activity out there. Most of that is free and it’s easier than ever to scrape it by the bucket load, generating a billion publication, congress, and social data points.

    Read more
  • KOL Identification and KOL Mapping

    The Relationship Between KOL Identification And KOL Mapping

    Among the infinite symposia, webinars, and white papers on this topic, “KOL identification” and “KOL mapping” can find themselves melting together in a gelatinous jargon stew. 

    Read more
  • KOL Research

    Studies On Adaptive Trials In Rare Cancer

    Rare cancers account for up to 20% of new cancer cases and Innovative Medicinal Products (InMP) are required to address this high unmet medical need. Adaptive trials may be an alternative to large randomized controlled trials for InMP development to target rare cancer patients.

    Read more
  • KOL Identification

    Unfeasibly Prolific Authors

    Using publication history from PubMed to help identify Experts or assess an individual KOLs work?

    Read more